Chronic treatment with the dual SGLT-1-2 inhibitor sotagliflozin was effective in mitigating left atria cardiomyopathy in this rat model of metabolic syndrome-related HFpEF [26]. Here, SLC5A1 is linked to cardiomyopathy.